More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control ...

More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The ...

So far, there is no "magic bullet" to cure HIV for good, but scientists are making rapid progress.

The UAB Department of Microbiology and the Center for AIDS Research (CFAR) hosted the inaugural HIV Basic and Translational Research Symposium Wednesday, Oct. 23, 2024, at the UAB Hilton Hotel. The ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating-and possibly even curing-the disease a seemingly insurmountable obstacle to achieve. But ...

There is still no cure or effective vaccine for HIV-1, which remains a public health threat. But scientists have opened up new possibilities in HIV treatment and vaccine development. A Step Towards a ...

New study estimates major lifetime health and cost burden from frailty and falls in people with HIV, highlighting need for prevention.

In a recent landmark study, scientists have unveiled how HIV-1 penetrates the cell's nuclear barrier—a discovery that could reshape antiviral strategies. The research, led by Professor Peijun Zhang, ...

Godfrey Dzhivhuho has dedicated his career to understanding HIV and other infectious diseases, inspired by the epidemic he witnessed growing up. Raised in Warrenton-Kimberly, South Africa, the oldest ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating—and possibly even curing—the disease a seemingly insurmountable obstacle to achieve. But ...

Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human ...

Updated HIV post-exposure prophylaxis guidelines introduce new PEP regimens, shorten follow-up HIV testing, and refine management after occupational exposure when source patients have undetectable ...